<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056082</url>
  </required_header>
  <id_info>
    <org_study_id>KUMC-HSC-8919-02</org_study_id>
    <secondary_id>CDR0000271935</secondary_id>
    <secondary_id>N01-CN-15135</secondary_id>
    <nct_id>NCT00056082</nct_id>
  </id_info>
  <brief_title>Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women</brief_title>
  <official_title>A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or&#xD;
      recurrence of cancer. Celecoxib may be effective in preventing breast cancer in at-risk&#xD;
      women.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing breast cancer&#xD;
      in premenopausal women who are at risk of developing cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the change in proliferation in benign breast epithelial cells as measured by&#xD;
           Ki-67/MIB-1 in premenopausal women at high risk for estrogen receptor-negative breast&#xD;
           cancer treated with celecoxib.&#xD;
&#xD;
        -  Determine the feasibility of this regimen by dropout rate of these patients during 12&#xD;
           months of treatment and compliance.&#xD;
&#xD;
        -  Determine the proportion of these women likely to express cyclooxygenase-2 protein&#xD;
           (COX-2) in at least 10% of benign ductal epithelial cells.&#xD;
&#xD;
        -  Compare the success rate of obtaining adequate ductal epithelial cells by random&#xD;
           periareolar fine needle aspiration (FNA) and ductal lavage in these patients before vs&#xD;
           after 12 months of a prevention intervention.&#xD;
&#xD;
        -  Assess pain associated with FNA and ductal lavage in these women.&#xD;
&#xD;
        -  Correlate, if possible, serum proteomics pattern with cytologic assessment and&#xD;
           mammographic density at baseline and at 12 months in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive oral celecoxib twice daily. Treatment continues for 12 months in the absence&#xD;
      of clinical evidence of cancer confirmed by biopsy or unacceptable toxicity.&#xD;
&#xD;
      Patients are assessed at baseline and at 12 months for mammographic breast density, serum&#xD;
      hormone levels, and serum IGF-1/IGFBP-3. Patients undergo ductal lavage or fine needle&#xD;
      aspiration for assessment of supernatant proteomics and breast biomarkers.&#xD;
&#xD;
      Patients are followed at 2 weeks and then annually for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 110 patients will be accrued for this study within 10-14&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Celecoxib 400 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celecoxib 400 mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>Celecoxib daily for 12 months</description>
    <arm_group_label>Celecoxib 400 mg bid</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Increased risk for breast cancer on the basis of at least 1 of the following criteria:&#xD;
&#xD;
               -  Five-year Gail risk at least 1.7% or a calculated risk at least 5 times the&#xD;
                  average for age group&#xD;
&#xD;
                    -  20-29 years old - calculated 5-year Gail risk is at least 0.1%&#xD;
&#xD;
                    -  30-39 years old - calculated 5-year Gail risk is at least 1.0%&#xD;
&#xD;
                    -  40 and over - calculated 5-year Gail risk is at least 1.7%&#xD;
&#xD;
               -  Known BRCA1/BRCA2 mutation carrier&#xD;
&#xD;
               -  Family history consistent with hereditary breast cancer, as defined by any of the&#xD;
                  following circumstances:&#xD;
&#xD;
                    -  At least 4 relatives with breast cancer at any age&#xD;
&#xD;
                    -  At least 2 first-degree relatives diagnosed with breast cancer at age 50 or&#xD;
                       younger&#xD;
&#xD;
                    -  Breast and ovarian cancer diagnosed in the same relative&#xD;
&#xD;
                    -  At least 2 occurrences of breast cancer and 1 occurrence of ovarian cancer&#xD;
                       at any age in the same family&#xD;
&#xD;
               -  Prior biopsy exhibiting atypical hyperplasia, lobular cancer in situ, ductal&#xD;
                  carcinoma in situ (DCIS)*, or invasive cancer** NOTE: *If DCIS or T1a or T1b&#xD;
                  disease was found, at least 2 months must have elapsed since prior surgery and/or&#xD;
                  radiotherapy to the involved breast&#xD;
&#xD;
        NOTE: **Prior invasive cancer (T1c, T2, or T3) must have been diagnosed at least 2 years&#xD;
        before study and be estrogen receptor-negative, node negative&#xD;
&#xD;
          -  Must have had a random periareolar fine needle aspiration successfully performed&#xD;
             within the past 3 months, with at least 1,000 cells on cytology slide and 3 additional&#xD;
             slides for biomarker analysis (1 with at least 500 cells for Ki-67 and 2 with at least&#xD;
             100 ductal cells for estrogen receptors and COX-2)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor negative&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 55&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Premenopausal, defined as menstrual periods estimated to occur every 21 to 35 days&#xD;
             over the past 6 months&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 5 years&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  No bleeding diathesis within the past year&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Albumin at least 3.0 g/dL&#xD;
&#xD;
          -  AST and ALT no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times ULN&#xD;
&#xD;
          -  No severe liver disease requiring treatment&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No high blood pressure not controlled by medication&#xD;
&#xD;
          -  No history of angina&#xD;
&#xD;
          -  No history of cardiovascular disease&#xD;
&#xD;
          -  No history of deep vein thrombosis&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No history of pulmonary embolism&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergy to sulfa, COX-2 inhibitors, or nonsteroidal anti-inflammatory drugs&#xD;
             (NSAIDs)&#xD;
&#xD;
          -  No history of an ulcer requiring treatment&#xD;
&#xD;
          -  No history of ulcerative colitis&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No body mass index &gt; 33&#xD;
&#xD;
          -  No history of diabetes&#xD;
&#xD;
          -  No prior metastatic malignancy of any kind&#xD;
&#xD;
          -  No complications of alcoholism requiring hospitalization&#xD;
&#xD;
          -  No concurrent asthma being treated&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 6 months since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 6 months since prior antihormone therapy (e.g., selective estrogen-receptor&#xD;
             modulators or aromatase inhibitors)&#xD;
&#xD;
          -  Anticipated use of oral or IV corticosteroids must be less than 2 weeks per year&#xD;
&#xD;
          -  No change (stop or start) in hormonal therapy within the past 6 months (e.g.,&#xD;
             estrogen, progesterone, oral contraceptives, or fertility agents)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy to the contralateral breast involved in the study treatment&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 weeks since prior aspirin, rofecoxib, celecoxib, other COX-2 inhibitors, or&#xD;
             NSAIDs&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
&#xD;
          -  No other concurrent NSAIDs&#xD;
&#xD;
          -  No chronic angiotensin-converting enzyme inhibitors&#xD;
&#xD;
          -  No chronic furosemide*&#xD;
&#xD;
          -  No chronic fluconazole*&#xD;
&#xD;
          -  No chronic lithium NOTE: *Occasional concurrent use allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol J. Fabian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lynn Sage Comprehensive Breast Center at Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Carol Fabian, MD</investigator_full_name>
    <investigator_title>Director, Breast Cancer Prevention Unit</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Global results will be published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

